CRBU — Caribou Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1619856 ·
Last close
$0.48
Market Cap
$51.59M
52W High
$3.54
52W Low
$0.45
ADV30
3,102,337
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,499,000 | — | -25,339,000 | -24,282,000 | 142,774,000 | 26,194,000 | 44,672,000 |
| Mar 2026 | 2,397,000 | — | -26,280,000 | -25,085,000 | 148,998,000 | 12,057,000 | 46,980,000 |
| Dec 2025 | 3,941,000 | — | -28,453,000 | -26,488,000 | 175,367,000 | 12,360,000 | 53,192,000 |
| Sep 2025 | 2,198,000 | — | -29,400,000 | -27,548,000 | 194,984,000 | 11,144,000 | 53,139,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-101,251,000
Investing CF
$76,842,000
Financing CF
$7,049,000
CapEx
$-1,647,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.42
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-621,600,000
Inventory
—
Receivables
$2,363,000
ST Investments
$105,569,000
EBIT TTM
$-119,561,000
Pretax Income TTM
$-133,769,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$10,035,000
EBITDA
$-104,609,000
Free Cash Flow
$-59,605,500
Enterprise Value
$50,494,540
Total Cash
$112,314,000
Total Debt
$26,655,000
Shares Out
107,207,513
Trailing EPS
$-1.08
Book Value
$0.93
ROE
-78.3%
ROA
-36.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 11,159,000 | -136,194,000 | -148,125,000 | 175,367,000 | 53,192,000 | 122,175,000 | -110,992,000 |
| Dec 2024 | 9,994,000 | -166,616,000 | -149,105,000 | 313,313,000 | 60,362,000 | 252,951,000 | -138,200,000 |
| Dec 2023 | 34,477,000 | -116,059,000 | -102,070,000 | 432,209,000 | 63,808,000 | 368,401,000 | -93,291,000 |
| Dec 2022 | 13,851,000 | -106,399,000 | -99,421,000 | 373,765,000 | 72,894,000 | 300,871,000 | -90,966,000 |
TTM Snapshot
Revenues TTM
$11,203,000
NetIncome TTM
$-133,219,000
OpCashFlow TTM
—
Assets (Latest)
$148,998,000
Forward EPS
$-1.26
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $0.50 · spot: $0.46 · call volume: 42 · put volume: 26
Expected Move to 2026-10-16:
±$0.15
(32.59%) —
implied range
$0.31 –
$0.61
· ATM straddle on $0.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BKHA | Black Hawk Acquisition Corp | $51.21M | $12.33 | — |
| ELOX | Eloxx Pharmaceuticals, Inc. | $52.16M | $15.18 | — |
| INMB | Inmune Bio, Inc. | $50.79M | $1.83 | — |
| LONA | LeonaBio, Inc. | $54.17M | $5.75 | — |
| EXOZ | EXOZYMES INC. | $48.91M | $5.27 | — |
News headlines (Yahoo Finance, 1h cache)
In the hunt for reverse merger targets, Caribou could be prized game
2026-10-08 15:23 · Yahoo
Caribou to halt CAR-T work, lay off staff amid ‘challenging’ funding climate
2026-10-07 15:37 · Yahoo
CRBU Stock Crashes 35% Premarket — RBC Slashes Target By 90% After Caribou Scraps CAR-T Programs
2026-10-07 10:49 · Yahoo
Caribou Biosciences stock plunges 40% on halt of CAR-T programs
2026-10-06 21:17 · Yahoo
Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates
2026-08-13 22:05 · Yahoo
Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-13 20:05 · Yahoo
BMS and Gilead rule in the CAR-T space. Off-the-shelf developers aren’t trying to change that.
2026-07-29 13:49 · Yahoo
Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?
2026-07-09 13:40 · Yahoo
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
2026-06-29 12:00 · Yahoo
Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026
2026-06-11 12:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.